Q-omics provides the consensus-scored EXTL2P1 profile across patient tissues and cancer cell-line models. EXTL2P1 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EXTL2P1 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, EXTL2P1 RNA expression shows 11,261 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUSC, and THYM as cancer lineages where EXTL2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EXTL2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EXTL2P1 survival associations across molecular data types. EXTL2P1 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EXTL2P1 RNA expression–survival associations across cancer types. High EXTL2P1 expression shows unfavorable associations in KIRC, LIHC, LGG and COAD, but favorable associations in STAD and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EXTL2P1 RNA expression.
This table summarizes EXTL2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for EXTL2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EXTL2P1 shows lower tumor expression in THCA and higher tumor expression in LUSC, HNSC, COAD and STAD. The LUSC box plot shows higher EXTL2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.043, t-test p = .001).
This table shows molecular features associated with EXTL2P1 in patient tissues and cancer cell lines. In patient samples, EXTL2P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
